Tempus AI TEM is currently in its 10 th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year ...

Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other worst-performing stocks. Tempus AI nosedived by 19.23 percent on Wednesday to close at $53. ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Obesity is often a combination of genetic and lifestyle factors. Genetics can influence metabolic pathways, appetite control, and energy storage. Leptin resistance can lead to increased appetite ...

Shares of artificial intelligence (AI) company Tempus AI (NASDAQ: TEM) are down to the tune of 15.6% as of 11:13 a.m. ET on Wednesday, upended by a warning from investment management outfit Spruce ...

Tempus AI (NASDAQ:TEM) saw its stock decline by 4% after short-selling firm Spruce Point Capital released a scathing report questioning the company’s operations, leadership, and financial disclosures.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects ...

Tempus AI, Inc., (formerly Tempus Labs ... is substantially explained by the expected contributions from the Ambry Genetics acquisition and the new Pathos/AstraZeneca deal, two factors that ...